DPP4 and cardiac hypertrophy: DPP4−/− mice showed improved survival after experimental infarction, and treatment with 250 mg/kg/d sitagliptin for 8 weeks led to improved functional recovery after ischemia/reperfusion (I/R) injury through increased endothelial cell density, reduced myocardial hypertrophy and enhanced fibrosis [32, 33].